Ropes & Gray represented Novo Nordisk in a strategic collaboration and license agreement with IMMvention Therapeutic to develop oral therapies for sickle cell disease and other chronic conditions. The collaboration was announced on January 22. Financial terms were not disclosed.
The companies will jointly advance IMMvention’s portfolio of preclinical BACH1 inhibitors to candidate nomination, after which Novo Nordisk will be responsible for clinical development, regulatory submissions and commercialization worldwide. Novo Nordisk has an exclusive worldwide license to IMMvention’s BACH1 program.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associate Shuang Ci.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.